The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissione...

C1q nephropathy in the pediatric population: pathology and pathogenesis

“…This compares with the ISKDC study, where nearly 80% of patients with NS were found to be steroid-responsive, and less than 50% of these patients had either FR or SD, with 85% disease free at 10 years [54,55]. While the frequency of steroid-responsive NS in patients with C1q nephropathy seems to be much lower and the frequency of ESRD much higher than has been reported in the pediatric NS literature [56][57][58], many of the C1q nephropathy case series are heavily biased toward a steroid-resistant population.…”

Immunosuppressive Therapy in Children With Steroid-Resistant Nephrotic Syndrome

“…However, we found no statistically significant difference in hospitalization days and costs of hospitalization. Evidence on pharmacoeconomic evaluation of treatments for SRNS need to be identified to provide guidance for clinical practice (33).…”

Rituximab in refractory nephrotic syndrome

“…vincristine), antiproliferative immunosuppressants [e.g. mycophenolate mofetil (MMF), calcineurin inhibitors (CI) cyclosporin A and tacrolimus], immunomodulating drugs (levamisole), angiotensin converting enzyme inhibitors (ACE-I) and plasma exchange, are used [1,4]. Many of these treatments have significant side effects and are not always effective.…”